Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019
Carolyn T Bramante,Kenneth B Beckman,Tanvi Mehta,Amy B Karger,David J Odde,Christopher J Tignanelli,John B Buse,Darrell M Johnson,Ray H B Watson,Jerry J Daniel,David M Liebovitz,Jacinda M Nicklas,Ken Cohen,Michael A Puskarich,Hrishikesh K Belani,Lianne K Siegel,Nichole R Klatt,Blake Anderson,Katrina M Hartman,Via Rao,Aubrey A Hagen,Barkha Patel,Sarah L Fenno,Nandini Avula,Neha V Reddy,Spencer M Erickson,Regina D Fricton,Samuel Lee,Gwendolyn Griffiths,Matthew F Pullen,Jennifer L Thompson,Nancy E Sherwood,Thomas A Murray,Michael R Rose,David R Boulware,Jared D Huling,Blake Anderson,Riannon C Atwater,Nandini Avula,Kenny B Beckman,Hrishikesh K Belani,David R Boulware,Carolyn T Bramante,Jannis Brea,Courtney A Broedlow,John B Buse,Paula Campora,Anup Challa,Jill Charles,Grace Christensen,Theresa Christiansen,Ken Cohen,Bo Connelly,Srijani Datta,Nikita Deng,Alex T Dunn,Spencer M Erickson,Faith M Fairbairn,Sarah L Fenno,Daniel J Fraser,Regina D Fricton,Gwen Griffiths,Aubrey A Hagen,Katrina M Hartman,Audrey F Hendrickson,Jared D Huling,Nicholas E Ingraham,Arthur C Jeng,Darrell M Johnson,Amy B Karger,Nichole R Klatt,Erik A Kuehl,Derek D LaBar,Samuel Lee,David M Liebovitz,Sarah Lindberg,Darlette G Luke,Rosario Machicado,Zeinab Mohamud,Thomas A Murray,Rumbidzai Ngonyama,Jacinda M Nicklas,David J Odde,Elliott Parrens,Daniela Parra,Barkha Patel,Jennifer L Proper,Matthew F Pullen,Michael A Puskarich,Via Rao,Neha V Reddy,Naveen Reddy,Katelyn J Rypka,Hanna G Saveraid,Paula Seloadji,Arman Shahriar,Nancy Sherwood,Jamie L Siegart,Lianne K Siegel,Lucas Simmons,Isabella Sinelli,Palak Singh,Andrew Snyder,Maxwell T Stauffer,Jennifer Thompson,Christopher J Tignanelli,Tannon L Tople,Walker J Tordsen,Ray HB Watson,Beiqing Wu,Adnin Zaman,Madeline R Zolik,Lena Zinkl,
DOI: https://doi.org/10.1093/cid/ciae159
IF: 20.999
2024-05-01
Clinical Infectious Diseases
Abstract:Abstract Background Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death through 28 days by 58%, of emergency department visits/hospitalizations/death through 14 days by 42%, and of long COVID through 10 months by 42%. Methods COVID-OUT was a 2 × 3 randomized, placebo-controlled, double-blind trial that assessed metformin, fluvoxamine, and ivermectin; 999 participants self-collected anterior nasal swabs on day 1 (n = 945), day 5 (n = 871), and day 10 (n = 775). Viral load was quantified using reverse-transcription quantitative polymerase chain reaction. Results The mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (−0.56 log10 copies/mL; 95% confidence interval [CI], −1.05 to −.06; P = .027). Those who received metformin were less likely to have a detectable viral load than placebo at day 5 or day 10 (odds ratio [OR], 0.72; 95% CI, .55 to .94). Viral rebound, defined as a higher viral load at day 10 than day 5, was less frequent with metformin (3.28%) than placebo (5.95%; OR, 0.68; 95% CI, .36 to 1.29). The metformin effect was consistent across subgroups and increased over time. Neither ivermectin nor fluvoxamine showed effect over placebo. Conclusions In this randomized, placebo-controlled trial of outpatient treatment of SARS-CoV-2, metformin significantly reduced SARS-CoV-2 viral load, which may explain the clinical benefits in this trial. Metformin is pleiotropic with other actions that are relevant to COVID-19 pathophysiology. Clinical Trials Registration NCT04510194.
immunology,infectious diseases,microbiology